News & EventsFebruary 19, 2008 October 2007 July 3, 2007 |
 News and Events: Archived News2004 The October 2004 issue of The Journal of Urology publishes "Serum Proteomic Profiling Can Discriminate Prostate Cancer From Benign Prostates In Men With Total Prostate Specific Antigen Levels Between 2.5 and 15.0 NG/ML." This paper, co-authored by researchers at FDA/NCI; Correlogic's, Ben Hitt and Wes Wiggins; and others, presents our research on prostate cancer. Applying Correlogic's technology to the serum of men with elevated PSA, the research successfully discriminated between men with benign processes and men with prostate cancer. This included men with PSA within the diagnostic gray zone. On September 28, 2004, Dr. Timothy Coleman, Vice President of Research and Development for Correlogic, presented "A New Paradigm: Pattern Recognition and Clinical Proteomics" at BioJapan 2004. Dr. Coleman discussed the results of Correlogic's ongoing research on pattern recognition in disease detection in the Pharmacoproteome symposium, chaired by Dr. Yoshiji Fujita, Professor of Molecular Biology and Biotechnology, University of Sheffield. BioJapan is held quadrennially and brings together leading research organizations and institutions from around the world. On July 14, 2004, Correlogic responded to the FDA’s letter regarding regulation of OvaCheck®. Response letter from Peter Levine, President of Correlogic Systems, Inc. to FDA. In the July 2004 issue, Diagnostic Testing and Technology Report publishes What's Next for Correlogic? On June 21, 2004, together with the North Shore-Long Island Jewish (LIJ) Research Institute, Correlogic announced a collaboration to advance the validation research on OvaCheck®, Correlogic's pattern recognition blood test for the early detection of ovarian cancer. Rep. Steve Israel (NY) was central to the creation of this relationship, and North Shore's participation in this work was made possible by the generous contributions of The Lynne Cohen Foundation and Row for a Cure. Read the Press Release. On June 2, 2004, the peer-reviewed journal Endocrine-Related Cancer, published “High-Resolution Serum Proteomic Features for Ovarian Cancer Detection”, a paper co-authored by researchers at NCI/FDA, Correlogic’s Chief Science officer Ben Hitt, and others. This research, including the continued use of Correlogic’s technology, was a further extension our previously reported ovarian cancer results. On April 22, 2004, Peter Levine, President and CEO of Correlogic, appeared at the Biomedical Marketing Association's 26th Annual Conference in Boston, MA. He presented "The Importance of Partnerships in Technology Development and Commercialization in the Diagnostics Industry: A Case Study of Correlogic (OvaCheck™)". On April 19, 2004, the Philadelphia Inquirer writes about Correlogic’s work on ovarian cancer detection in the article, Progress From Unraveling Proteins. On April 14, 2004, the Miami Herald writes about Correlogic’s work on ovarian cancer detection in the article, New Jersey Oncologist Says Ovarian Cancer Test May Catch Disease Early. In March 2004, the peer-reviewed journal Toxicologic Pathology, publishes "Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection" a paper co-authored by Correlogic’s Chief Science officer Ben Hitt, researchers at the NCI/FDA, and others. This research is the first application of Correlogic’s pattern recognition approach and technology to drug toxicity -- a significant issue in disease treatment. Scientists identified patterns in mass spectra from sera that could identify rats treated with the cardiotoxic drug doxorubicin alone from those treated with doxorubicin and a cardioprotectant. These results suggest that, using Correlogic's technologies, such toxicities may be detectable before adverse effects become irreversible. Correlogic’s poster presentation “High-Throughput Multidimensional Mass Spectrometry Analysis for the Detection of Early Stage Epithelial Ovarian Cancer: A Serum Test for Ovarian Cancer.” appeared at the Society of Gynecological Investigation conference in Houston, TX on March 25, 2004. The poster presented results that were 97 percent sensitive and 94 percent specific in validation. February 10, 2004, Mitsui and Co., Ltd., Tokyo, Japan, makes equity investment in Correlogic. The companies will explore the creation of a joint venture in Japan. Read press release. On January 12, 2004, Judith Reichman, M.D., medical contributor of the Today Show, profiled OvaCheck®, a blood test for the early detection of ovarian cancer. New Tests and Therapies May Help Enhance the Lives of Women. View the interview with NBC's Ann Curry.
2003 On December 1, 2003, Peter Levine, President and CEO of Correlogic, addressed Rep. Steve Israel's (D-NY) Cancer Task Force. He spoke about the upcoming ovarian blood test and other technology. The event was attended by 50 representatives from cancer advocacy and support organizations, local government representatives and healthcare providers. In December 2003, the peer-reviewed journal Cancer Cell, published "Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse", a paper co-authored by Correlogic's Chief Science Officer, Ben Hitt, along with researchers at NCI/FDA and others. This study, using mouse models, utilized Correlogic's technology to detect pancreatic cancer. It was a demonstration of the applicability of our technology to another cancer—one in which the disease's typically rapid progression makes early detection particularly important. The December 2003 issue of Health Magazine writes about Correlogic's work on ovarian cancer detection in the article, Ovarian Cancer: A Tough Fight May Get Easier.
|